Molecular and phenotypic characteristics of respiratory syncytial virus isolates recovered from medically vulnerable children: An exploratory analysis of a phase 2/3 randomized, double-blind, palivizumab-controlled trial of nirsevimab (MEDLEY)

Authors

Kevin M. Tuffy (ORCID: https://orcid.org/0009-0007-8644-5025)
Deidre Wilkins (ORCID: https://orcid.org/0000-0002-7263-2600)
Bahar Ahani
Vaishali S. Mankad
Kenji Furuno (ORCID: https://orcid.org/0000-0003-3991-8348)
Ulrika Wählby Hamrén (ORCID: https://orcid.org/0000-0002-9761-9699)
Joseph B. Domachowske (ORCID: https://orcid.org/0000-0003-1510-1309)
Elizabeth J. Kelly (ORCID: https://orcid.org/0000-0002-6988-8576)
Shabir Ahmed Madhi (ORCID: https://orcid.org/0000-0002-7629-0636)
Yingyi Wang (ORCID: https://orcid.org/0000-0003-1704-4643)
Tonya Villafana (ORCID: https://orcid.org/0000-0001-7929-6374)
Hong Ji (ORCID: https://orcid.org/0000-0002-9382-1988)

Institutions

South African Medical Research Council (ZA)
University of the Witwatersrand (ZA)
SUNY Upstate Medical University (US)
Fukuoka Children's Hospital and Medical Center for Infectious Diseases (JP)
AstraZeneca (Finland) (FI)
AstraZeneca (Sweden) (SE)
AstraZeneca (United States) (US)

Publication Details

Journal: Vaccine
Published: 2024-09-05
DOI: https://doi.org/10.1016/j.vaccine.2024.126276
Citations: 3
Primary Topic: Respiratory viral infections research
Type: article
Field-Weighted Citation Impact: 1.16

Controls

|||

ALL TIME

JAN

FEB

MAR

APR

MAY

JUN

JUL

AUG

SEP

OCT

article

Molecular and phenotypic characteristics of respiratory syncytial virus isolates recovered from medically vulnerable children: An exploratory analysis of a phase 2/3 randomized, double-blind, palivizumab-controlled trial of nirsevimab (MEDLEY)

Kevin M. Tuffy, Deidre Wilkins, Bahar Ahani, Vaishali S. Mankad et al.

Sep 5, 2024

3 citations

Vaccine

Respiratory viral infections research

1.16

article

Molecular and phenotypic characteristics of respiratory syncytial virus isolates recovered from medically vulnerable children: An exploratory analysis of a phase 2/3 randomized, double-blind, palivizumab-controlled trial of nirsevimab (MEDLEY)

Kevin M. Tuffy, Deidre Wilkins, Bahar Ahani, Vaishali S. Mankad, Kenji Furuno, Ulrika Wählby Hamrén, Joseph B. Domachowske, Elizabeth J. Kelly, Shabir Ahmed Madhi, Yingyi Wang, Tonya Villafana, Hong Ji

September 5, 2024article en

3 citations

Abstract

No abstract available for this paper.

VaccineVol. 42(24)

South African Medical Research Council (ZA), University of the Witwatersrand (ZA), SUNY Upstate Medical University (US), Fukuoka Children's Hospital and Medical Center for Infectious Diseases (JP), AstraZeneca (Finland) (FI), AstraZeneca (Sweden) (SE), AstraZeneca (United States) (US)

No poverty

Openalex Percentile: Top 20%

Respiratory viral infections research

1.16

DOI Open Access PDF OpenAlex

AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.